Your browser doesn't support javascript.
Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes.
Voss, William N; Hou, Yixuan J; Johnson, Nicole V; Delidakis, George; Kim, Jin Eyun; Javanmardi, Kamyab; Horton, Andrew P; Bartzoka, Foteini; Paresi, Chelsea J; Tanno, Yuri; Chou, Chia-Wei; Abbasi, Shawn A; Pickens, Whitney; George, Katia; Boutz, Daniel R; Towers, Dalton M; McDaniel, Jonathan R; Billick, Daniel; Goike, Jule; Rowe, Lori; Batra, Dhwani; Pohl, Jan; Lee, Justin; Gangappa, Shivaprakash; Sambhara, Suryaprakash; Gadush, Michelle; Wang, Nianshuang; Person, Maria D; Iverson, Brent L; Gollihar, Jimmy D; Dye, John M; Herbert, Andrew S; Finkelstein, Ilya J; Baric, Ralph S; McLellan, Jason S; Georgiou, George; Lavinder, Jason J; Ippolito, Gregory C.
  • Voss WN; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
  • Hou YJ; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Johnson NV; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
  • Delidakis G; Department of Chemical Engineering, The University of Texas at Austin, Austin, TX, USA.
  • Kim JE; Department of Biomedical Engineering, The University of Texas at Austin, Austin, TX, USA.
  • Javanmardi K; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
  • Horton AP; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
  • Bartzoka F; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
  • Paresi CJ; Department of Chemistry, The University of Texas at Austin, Austin, TX, USA.
  • Tanno Y; Department of Chemical Engineering, The University of Texas at Austin, Austin, TX, USA.
  • Chou CW; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
  • Abbasi SA; U.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD, USA.
  • Pickens W; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
  • George K; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
  • Boutz DR; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
  • Towers DM; CCDC Army Research Laboratory-South, The University of Texas at Austin, Austin, TX, USA.
  • McDaniel JR; Department of Chemical Engineering, The University of Texas at Austin, Austin, TX, USA.
  • Billick D; Biomedicine Design, Pfizer, Cambridge, MA, USA.
  • Goike J; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
  • Rowe L; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
  • Batra D; Biotechnology Core Facility Branch, Division of Scientific Resources, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Pohl J; Tulane National Primate Research Center Department of Microbiology 18703 Three Rivers Road Covington, LA, USA.
  • Lee J; Biotechnology Core Facility Branch, Division of Scientific Resources, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Gangappa S; Biotechnology Core Facility Branch, Division of Scientific Resources, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Sambhara S; Biotechnology Core Facility Branch, Division of Scientific Resources, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Gadush M; Immunology and Pathogenesis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Wang N; Immunology and Pathogenesis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Person MD; Center for Biomedical Research Support, The University of Texas at Austin, Austin, TX, USA.
  • Iverson BL; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
  • Gollihar JD; Center for Biomedical Research Support, The University of Texas at Austin, Austin, TX, USA.
  • Dye JM; Department of Chemistry, The University of Texas at Austin, Austin, TX, USA.
  • Herbert AS; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
  • Finkelstein IJ; CCDC Army Research Laboratory-South, The University of Texas at Austin, Austin, TX, USA.
  • Baric RS; Department of Pathology and Genomic Medicine, Houston Methodist Research Institute, Houston Methodist Hospital, Houston, TX, USA.
  • McLellan JS; U.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD, USA.
  • Georgiou G; U.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD, USA.
  • Lavinder JJ; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
  • Ippolito GC; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Science ; 372(6546): 1108-1112, 2021 06 04.
Article in English | MEDLINE | ID: covidwho-1388437
ABSTRACT
The molecular composition and binding epitopes of the immunoglobulin G (IgG) antibodies that circulate in blood plasma after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are unknown. Proteomic deconvolution of the IgG repertoire to the spike glycoprotein in convalescent subjects revealed that the response is directed predominantly (>80%) against epitopes residing outside the receptor binding domain (RBD). In one subject, just four IgG lineages accounted for 93.5% of the response, including an amino (N)-terminal domain (NTD)-directed antibody that was protective against lethal viral challenge. Genetic, structural, and functional characterization of a multidonor class of "public" antibodies revealed an NTD epitope that is recurrently mutated among emerging SARS-CoV-2 variants of concern. These data show that "public" NTD-directed and other non-RBD plasma antibodies are prevalent and have implications for SARS-CoV-2 protection and antibody escape.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunoglobulin G / Antibodies, Neutralizing / Spike Glycoprotein, Coronavirus / SARS-CoV-2 / COVID-19 / Antibodies, Viral Topics: Variants Limits: Animals / Humans Language: English Journal: Science Year: 2021 Document Type: Article Affiliation country: SCIENCE.ABG5268

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunoglobulin G / Antibodies, Neutralizing / Spike Glycoprotein, Coronavirus / SARS-CoV-2 / COVID-19 / Antibodies, Viral Topics: Variants Limits: Animals / Humans Language: English Journal: Science Year: 2021 Document Type: Article Affiliation country: SCIENCE.ABG5268